Oral targeting of protein kinase C receptor: Promising route for diabetic retinopathy?

Current Drug Delivery

Volumn 9, Issue 4, 2012, Pages 405-413

  Pathak, Deepa ^a   Gupta, Ankur ^a   Kamble, Bhagyashree ^a   Gowthamarajan, Kuppusamy ^a   Suresh, Bhojraj ^a  

^a JSS COLLEGE OF PHARMACY   (India)

Author keywords

Diabetic retinopathy; Inhibitors; Novel drug delivery approach; PKC; VEGF

Indexed keywords

ACETAZOLAMIDE; AFLIBERCEPT; AMINOGUANIDINE; ANTIOXIDANT; BEVACIZUMAB; DEXAMETHASONE; DIACYLGLYCEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FLUOCINOLONE ACETONIDE; HYALURONIDASE; I VATION; OCRIPLASMIN; OCTREOTIDE; PEGAPTANIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLASMIN; POSIDUREX; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C DELTA; PROTEIN KINASE C EPSILON; PROTEIN KINASE C ETA; PROTEIN KINASE C GAMMA; PROTEIN KINASE C INHIBITOR; RANIBIZUMAB; RUBOXISTAURIN; SORBITOL; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ARTICLE; BLOOD VESSEL PERMEABILITY; BRAIN; CATARACT; CENTRAL RETINA VEIN OCCLUSION; CONJUNCTIVAL HEMORRHAGE; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG PENETRATION; DRUG STABILITY; DRUG TARGETING; ENDOPHTHALMITIS; ENZYME ACTIVATION; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; IRITIS; MOLECULAR WEIGHT; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA ISCHEMIA; SIDE EFFECT; SPLEEN; STIMULUS RESPONSE; TISSUE LEVEL; VISUAL ACUITY;

EID: 84863553729     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/156720112801323080     Document Type: Article

References (39)

1. Raman, R.; Rani, P.K.; Reddi, R.S. Prevalence of diabetic retinopathy in India: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study report 2. Ophthalmology, 2009, 116, 311-318.
2. Sloan, F.A.; Belsky, D.; Ruiz, D.; Lee, P. Changes in incidence of diabetes mellitus-related eye disease among US elderly persons. 1994-2005. Arch. Ophthalmol., 2008, 126, 1548-1553.
3. Kaiser, N.; Sasson, S.; Feener, E.P. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes, 1993, 42, 80-89.
4. Koya, D.; King, G.L. Protein kinase C activation and development of diabetes complications. Diabetes, 1998, 47, 859-866.
5. Derubertis, F.R.; Craven, P.A. Activation of protein kinase C in glomerular cells in diabetes: Mechanism and potential link to the pathogenesis of diabetic glomerulopathy. Diabetes, 1994, 43, 1-8.
6. Williams, B. Glucose-induced vascular smooth muscle dysfunction: the role of protein kinase C. J. Hypertens, 1995, 13, 477-486.
7. Baynes, J.W. Role of oxidative stress in development of complications in diabetes. Diabetes, 1991, 40, 405-412.
8. rd ed.; London and New York, Martin Dunitz, 2003.
9. Donnelly, R. Protein kinase C: a novel therapeutic target in macrovascular complications. Mod. Diabetes Manag., 2000, 1, 13-16.
10. George, L.K.; Evcimen, N.D. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol. Res., 2007, 55, 498-510.
11. Hofmann, J. The potential for isoenzymes-selective modulation of protein kinase C. FASEB J., 1997, 11, 649-669.
12. Mellor, H.; Parker, P.J. The extende protein kinase C superfamily. Biochem. J., 1998, 332, 281-292.
13. William, C.W.; Khan, W.A.; Merchenthaler, I. Tissue and Cellular Distribution of the Extended Family of Protein Kinase C Isoenzymes. J. Chem. Biol., 1992, 117, 121-133.
14. Ferrata, N.; Gerber, H.P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med., 2003, 9, 669-676.
15. Wirostko, B.; Wong, T.Y.; Simo, R. Vascular endothelial growth factor and diabetic complicatins. Prog. Retinal Eye Res., 2008, 27, 608-621.
16. Tonello, M.; Costa, R.A.; Almeida, F.P. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHistudy). Acta Ophthalmol., 2008, 86, 385-389.
17. Mirshahi, A.; Roohipoor, R.; Lashay, A. Bevacizumab augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur. J. Ophthalmol., 2008, 18, 263-269.
18. Jorge, R.; Costa, R.A.; Calucci, D. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina, 2006, 26, 1006-1013.
19. National PBM Drug Monograph. Ranibizumab, November 2006, 1-9.
20. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology, 2008, 11, 1447-1449.
21. Rachmaniab, R.; Lidarab, M.; Levyab, Z; Mordchai, R. Effect of enalapril on the incidence of retinopathy in normotensive patients with type 2 diabetes. Diabetes, 2000, 11, 48-50.
22. Zhi-Liang, W.; Wo-Dong, S.; Min, L.; Xiao-Ping, B. Pharmacologic vitreolysis with plasmin and hyaluronidase in diabetic rats. Retina, 2009, 29, 269-274.
23. Mincione, F.; Scozzafava, A.; Supuran, C.T. The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr. Pharm. Des., 2008, 14, 649-654.
24. Haupt, E.; Lederman, H.; Kopcke, W. Benfotiamine in the Treatment of Diabetic Polyneuropathy-a Three Week Randomized, Controlled Pilot Study. Int. J. Clin. Pharmacol. Therapy and Toxicol 2005. PubMed.gov. National Library of Medicine and the National Institutes of Health, 2007, 9, 304.
25. Gehrs, K.M. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study: response to Grant et al. (Letter). Diabetes Care, 2000, 24, 182.
26. Hamada, Y.; Nakamura, J.; Naruse, K. Epalrestat, an aldose reductase ihibitor reduces the levels of Nepsilon-(carboxymethyl) lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care, 2000, 23, 1539-1544.
27. Raskin, P.; Cattran, D.; Williams, M. Pimagedine Reduces Progression of Retinopathy and Lowers Lipid Levels in Patients with Type 1 Diabetes Mellitus was presented as a poster session on Sunday; November 7, 1999.
28. Aiello, L.P.; Shen, L.Q.; Child, A. Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch. Ophthalmol., 2008, 126, 793-799.
29. Jennifer, L.B.; Kristina, M.C.; Robert, B.; Douglas, O.B.; James, R.; Charles, B.; David, S. Diposition of 14 C Ruboxistaurin in humans. A Soc. Pharmacol. and experiment. Therap., 2000, 34, 1909-1917.
30. Hideaki, H.; Nakamura, S.; Chikaraishi, Y. Ruboxistaurin a PKC inhibitor inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt. Exp. Eye Res., 2010, 90, 137-145.
31. Ferrara, N.; Ferrara, K.J.; Novotny, W. Bevacizumab (Avastin) a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun., 2005, 333, 328-335.
32. Kourlas, H.; Abrams, P. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin. Therap., 2007, 29, 1-10
33. National PBM Drug Monograph. Ranibizumab (Lucentis®) November 2006.
34. Mitra, A.K. Ophthalmic drug delivery systems; Marcel Dekker Inc:New York Basel, Hongkong 1993; Vol 58, pp. 437-455.
35. Engel, G.L.; Farid, N.A.; Faul, M.M. Salt form selction and characterization of LY333531 mesylate monohydrate. Int. J. Pharm., 2000, 198, 239-247.
36. Burkey, J.L.; Campanale, K.M.; Barbuch, R. Disposition of [14C] Ruboxistaurin in humans. A Soc. Pharmacol. Exp. Therap., 2006, 34, 1909-1917.
37. Ishii, H.; Koya, D.; King, G.L. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J. Mol. Med., 1998, 76, 21-31.
38. Way, K.J.; Chou, E.; King, G.L. Identification of PKC-isoformspecific biological actions using pharmacological approaches. Trends Pharmacol. Sci., 2000, 21, 181-187.
39. Frank, R.N. Potential new medical therapies for diabetic retinopathy: Protein kinase C inhibitors. A. J. Ophthalmol., 2002, 133, 693-698.